Art Levin trades the C-suite for pair of roles at Avid­i­ty; Ex-Mer­ck CEO Ken Fra­zier to chair an­oth­er com­pa­ny

Art Levin is call­ing it a day as CSO of Avid­i­ty Bio­sciences, but he’s not go­ing any­where: He’s been giv­en the ti­tle of “dis­tin­guished sci­en­tist and strate­gic leader” and will join the board of di­rec­tors. Chief tech­ni­cal of­fi­cer Michael Flana­gan will be el­e­vat­ed to chief sci­en­tif­ic and tech­ni­cal of­fi­cer.

Levin, Flana­gan and CEO Sarah Boyce spoke to End­points News in De­cem­ber about ear­ly-stage da­ta for Avid­i­ty’s siR­NA ther­a­py in my­oton­ic dy­s­tro­phy type 1, AOC 1001. The FDA is­sued a par­tial clin­i­cal hold on the drug less than two months ear­li­er, cit­ing a se­ri­ous ad­verse event. Avid­i­ty has the dis­tinc­tion of own­ing the tick­er $RNA and shares sky­rock­et­ed more than 80% af­ter the da­ta were re­leased.

Endpoints News

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.